BR0108723A - Medicamentos contra doenças viróticas - Google Patents

Medicamentos contra doenças viróticas

Info

Publication number
BR0108723A
BR0108723A BR0108723-1A BR0108723A BR0108723A BR 0108723 A BR0108723 A BR 0108723A BR 0108723 A BR0108723 A BR 0108723A BR 0108723 A BR0108723 A BR 0108723A
Authority
BR
Brazil
Prior art keywords
viral diseases
against viral
medicines against
isoxazoles
medicines
Prior art date
Application number
BR0108723-1A
Other languages
English (en)
Inventor
Michael Brands
Susanne Nikolic
Peter Eckenberg
Marcus Bauser
Johannes Kaulen
Arnold Paessens
Erwin Graef
Olaf Weber
Stefan Lottmann
Karl-Heinz Schlemmer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000109408 external-priority patent/DE10009408A1/de
Priority claimed from DE2000132874 external-priority patent/DE10032874A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0108723A publication Critical patent/BR0108723A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MEDICAMENTOS CONTRA DOENçAS VIRóTICAS". A invenção refere-se a isoxazóis que são agentes antivirais altamente eficazes. Combinações de isoxazóis, dihidropirimidinas e/ou lamivudin e eventualmente interferona inibem a multiplicação de vírus HBV melhor do que os agentes conhecidos até agora
BR0108723-1A 2000-02-28 2001-02-19 Medicamentos contra doenças viróticas BR0108723A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000109408 DE10009408A1 (de) 2000-02-28 2000-02-28 Arzneimittel gegen virale Erkrankungen
DE2000132874 DE10032874A1 (de) 2000-07-06 2000-07-06 Arzneimittelkombinationen gegen virale Erkrankungen
PCT/EP2001/001825 WO2001064755A2 (de) 2000-02-28 2001-02-19 Isoxazole gegen virale erkrankungen

Publications (1)

Publication Number Publication Date
BR0108723A true BR0108723A (pt) 2002-12-03

Family

ID=26004561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108723-1A BR0108723A (pt) 2000-02-28 2001-02-19 Medicamentos contra doenças viróticas

Country Status (13)

Country Link
US (1) US20030187028A1 (pt)
EP (1) EP1286974A2 (pt)
JP (1) JP2003526639A (pt)
KR (1) KR20020079963A (pt)
CN (1) CN1406233A (pt)
AU (1) AU3739801A (pt)
BR (1) BR0108723A (pt)
CA (1) CA2401405A1 (pt)
IL (1) IL151188A0 (pt)
MX (1) MXPA02008418A (pt)
PL (1) PL365124A1 (pt)
TR (1) TR200201954T2 (pt)
WO (1) WO2001064755A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1962841A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013144129A1 (en) * 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014124092A2 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts
CN109970675A (zh) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 一组硫脲化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2126329A (en) * 1936-03-20 1938-08-09 Hoffmann La Roche Amide derivatives of isoxazole carboxylic acids
DE69305093T2 (de) * 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
DE69937904T2 (de) * 1998-03-11 2009-01-02 James W. Oak Park Williams Antivirale verwendungen von leflunomid produkten

Also Published As

Publication number Publication date
JP2003526639A (ja) 2003-09-09
TR200201954T2 (tr) 2002-12-23
MXPA02008418A (es) 2003-02-12
US20030187028A1 (en) 2003-10-02
KR20020079963A (ko) 2002-10-21
AU3739801A (en) 2001-09-12
EP1286974A2 (de) 2003-03-05
WO2001064755A3 (de) 2002-06-20
WO2001064755A2 (de) 2001-09-07
IL151188A0 (en) 2003-04-10
CA2401405A1 (en) 2001-09-07
PL365124A1 (en) 2004-12-27
CN1406233A (zh) 2003-03-26

Similar Documents

Publication Publication Date Title
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
BRPI0411900A (pt) compostos antivirais e métodos
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
DE69909756D1 (de) Antivirale pyrimidinderivate
AU2003291998A8 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO1995000638A3 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
DK1280813T3 (da) Antivirale pyrimidin-nukleosidanaloger
ES2051641B1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
IL145884A0 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
EP1256348A4 (en) REMEDIES AGAINST HEPATITIS
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
BR0111393A (pt) Métodos de tratamento de doenças virais com il-18 e suas combinações
AP2049A (en) Medicament containing activated antithrombin III
BR9810556A (pt) Beta-alcoxiacrilatos contra a malária
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.
ATE238062T1 (de) Hemmung von hiv-infektion
NO20021856L (no) Koplingsdal
DE69937904D1 (de) Antivirale verwendungen von leflunomid produkten
PY0101564A (es) Triazine containing anionic compounds useful as antiviral agents
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]